Compounds > truxillic acid
Page last updated: 2024-12-07

truxillic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

truxillic acid: RN given refers to cpd with unspecified isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID78213
CHEMBL ID1098368
CHEMBL ID4277988
SCHEMBL ID3482620
SCHEMBL ID15590565
SCHEMBL ID4560501
SCHEMBL ID18674152
SCHEMBL ID20598122
SCHEMBL ID21120223
SCHEMBL ID20614651
MeSH IDM0044831

Synonyms (63)

Synonym
HMS1473D03
einecs 224-724-3
CBDIVE_013278
OPREA1_453209
IDI1_019387
nsc103001
nsc-103001
490-20-0
CHEMDIV3_000069
4462-95-7
EC-000.1430
2,4-diphenyl-1,3-cyclobutanedicarboxylic acid
truxillic acid
NCGC00172589-01
AKOS001483772
2,4-diphenylcyclobutane-1,3-dicarboxylic acid
CHEMBL1098368
ALPHA-TRUXILLIC ACID ,
2,4-diphenyl-cyclobutane-1,3-dicarboxylic acid
CCG-103288
821bb4r21v ,
cocaic acid
unii-821bb4r21v
1,3-cyclobutanedicarboxylic acid, 2,4-diphenyl-, (1alpha,2alpha,3beta,4beta)-
truxillic acid, alpha-isomer
truxillic acid alpha-isomer [mi]
truxillic acid alpha-isomer
nsc 103001
gratissimic acid
FT-0600226
truxillic acid, .alpha.-isomer
1,3-cyclobutanedicarboxylic acid, 2,4-diphenyl-, (1.alpha.,2.alpha.,3.beta.,4.beta.)-
truxillic acid .alpha.-isomer
.alpha.-truxillic acid
truxillic acid [mi]
AB01330753-02
SCHEMBL3482620
SCHEMBL15590565
SCHEMBL4560501
2,4-diphenyl-1,3-cyclobutanedicarboxylic acid #
1,3-cyclobutanedicarboxylic acid, 2,4-diphenyl-
QWFRRFLKWRIKSZ-UHFFFAOYSA-N
DTXSID20196252
SCHEMBL18674152
1,3-diphenylcyclobutane-2,4-dicarboxylic
sr-01000078302
SR-01000078302-1
SCHEMBL20598122
SCHEMBL21120223
Q6172554
2beta,4alpha-diphenyl-1beta,3alpha-cyclobutanedicarboxylic acid
HY-114771
CS-0064284
Q27269288
rel-(1r,2r,3s,4s)-2,4-diphenylcyclobutane-1,3-dicarboxylic acid
NCGC00172589-02
MS-24244
SCHEMBL20614651
CHEMBL4277988 ,
bdbm50468455
DTXSID501316746
??-truxillic acid
AKOS040732416
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, heartHomo sapiens (human)Ki10.00000.25005.90809.3000AID1404705
Fatty acid-binding protein 5Homo sapiens (human)Ki10.00000.24802.77129.3700AID1404706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
nervous system developmentFatty acid-binding protein, brainHomo sapiens (human)
negative regulation of cell population proliferationFatty acid-binding protein, brainHomo sapiens (human)
epithelial cell proliferationFatty acid-binding protein, brainHomo sapiens (human)
fatty acid transportFatty acid-binding protein, brainHomo sapiens (human)
negative regulation of cell population proliferationFatty acid-binding protein, heartHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, heartHomo sapiens (human)
intracellular lipid transportFatty acid-binding protein, heartHomo sapiens (human)
cholesterol homeostasisFatty acid-binding protein, heartHomo sapiens (human)
regulation of fatty acid oxidationFatty acid-binding protein, heartHomo sapiens (human)
brown fat cell differentiationFatty acid-binding protein, heartHomo sapiens (human)
phospholipid homeostasisFatty acid-binding protein, heartHomo sapiens (human)
positive regulation of phospholipid biosynthetic processFatty acid-binding protein, heartHomo sapiens (human)
positive regulation of long-chain fatty acid import into cellFatty acid-binding protein, heartHomo sapiens (human)
regulation of phosphatidylcholine biosynthetic processFatty acid-binding protein, heartHomo sapiens (human)
glucose metabolic processFatty acid-binding protein 5Homo sapiens (human)
lipid metabolic processFatty acid-binding protein 5Homo sapiens (human)
phosphatidylcholine biosynthetic processFatty acid-binding protein 5Homo sapiens (human)
epidermis developmentFatty acid-binding protein 5Homo sapiens (human)
negative regulation of glucose transmembrane transportFatty acid-binding protein 5Homo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein 5Homo sapiens (human)
regulation of prostaglandin biosynthetic processFatty acid-binding protein 5Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayFatty acid-binding protein 5Homo sapiens (human)
glucose homeostasisFatty acid-binding protein 5Homo sapiens (human)
regulation of sensory perception of painFatty acid-binding protein 5Homo sapiens (human)
regulation of retrograde trans-synaptic signaling by endocanabinoidFatty acid-binding protein 5Homo sapiens (human)
positive regulation of cold-induced thermogenesisFatty acid-binding protein 5Homo sapiens (human)
lipid transport across blood-brain barrierFatty acid-binding protein 5Homo sapiens (human)
fatty acid transportFatty acid-binding protein 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
protein bindingFatty acid-binding protein, brainHomo sapiens (human)
lipid bindingFatty acid-binding protein, brainHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, brainHomo sapiens (human)
protein bindingFatty acid-binding protein, heartHomo sapiens (human)
cytoskeletal protein bindingFatty acid-binding protein, heartHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, heartHomo sapiens (human)
oleic acid bindingFatty acid-binding protein, heartHomo sapiens (human)
retinoic acid bindingFatty acid-binding protein 5Homo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein 5Homo sapiens (human)
fatty acid bindingFatty acid-binding protein 5Homo sapiens (human)
protein bindingFatty acid-binding protein 5Homo sapiens (human)
lipid bindingFatty acid-binding protein 5Homo sapiens (human)
identical protein bindingFatty acid-binding protein 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
cytosolFatty acid-binding protein, brainHomo sapiens (human)
nucleusFatty acid-binding protein, brainHomo sapiens (human)
cytosolFatty acid-binding protein, brainHomo sapiens (human)
extracellular spaceFatty acid-binding protein, heartHomo sapiens (human)
cytosolFatty acid-binding protein, heartHomo sapiens (human)
extracellular exosomeFatty acid-binding protein, heartHomo sapiens (human)
nucleusFatty acid-binding protein, heartHomo sapiens (human)
cytosolFatty acid-binding protein, heartHomo sapiens (human)
extracellular regionFatty acid-binding protein 5Homo sapiens (human)
nucleusFatty acid-binding protein 5Homo sapiens (human)
nucleoplasmFatty acid-binding protein 5Homo sapiens (human)
cytoplasmFatty acid-binding protein 5Homo sapiens (human)
cytosolFatty acid-binding protein 5Homo sapiens (human)
plasma membraneFatty acid-binding protein 5Homo sapiens (human)
postsynaptic densityFatty acid-binding protein 5Homo sapiens (human)
secretory granule membraneFatty acid-binding protein 5Homo sapiens (human)
azurophil granule lumenFatty acid-binding protein 5Homo sapiens (human)
synapseFatty acid-binding protein 5Homo sapiens (human)
extracellular exosomeFatty acid-binding protein 5Homo sapiens (human)
cytosolFatty acid-binding protein 5Homo sapiens (human)
nucleusFatty acid-binding protein 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1404708Antinociceptive activity in C57BL/6 mouse model of complete Freund's adjuvant-induced inflammatory pain assessed as increase in paw withdrawal latency at 40 mg/kg, ip measured after 90 mins by plantar test2018European journal of medicinal chemistry, Jun-25, Volume: 154SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
AID1404705Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay2018European journal of medicinal chemistry, Jun-25, Volume: 154SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
AID1404707Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay2018European journal of medicinal chemistry, Jun-25, Volume: 154SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
AID1404706Displacement of DAUDA from recombinant human N-terminal His-tagged FABP5 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay2018European journal of medicinal chemistry, Jun-25, Volume: 154SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID479484Agonist activity at human PPARdelta at 10 uM by Gal4 transactivation assay relative to pioglitazone2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Truxillic acid derivatives act as peroxisome proliferator-activated receptor gamma activators.
AID479483Agonist activity at human PPARalpha at 10 uM by Gal4 transactivation assay relative to pioglitazone2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Truxillic acid derivatives act as peroxisome proliferator-activated receptor gamma activators.
AID479482Agonist activity at human PPARgamma at 10 uM by Gal4 transactivation assay relative to pioglitazone2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Truxillic acid derivatives act as peroxisome proliferator-activated receptor gamma activators.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.11)18.7374
1990's2 (11.11)18.2507
2000's5 (27.78)29.6817
2010's6 (33.33)24.3611
2020's3 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.06 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index44.36 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.4320aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.0310aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.0110glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
diphenyl
diphenyl: RN given refers to unlabeled cpd; structure		2.4110aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative
cyclohexanol
Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.		210cyclohexanols;
secondary alcohol		solvent
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		210D-glucopyranoseepitope;
mouse metabolite
n-methylscopolamine
N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.		710
e-z cinnamic acid
cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid		2.0210cinnamic acidplant metabolite
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.4120benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0110prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
gantacurium
gantacurium: Neuromuscular Depolarizing Agents; structure in first source		3.1210
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Innate Inflammatory Response
[description not available]		02.4110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.4110
Ache
[description not available]		02.610
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.610
Anaphylactic Reaction
[description not available]		02.9410
Tachyarrhythmia
[description not available]		02.9410
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		02.9410
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.		02.9410